Menu
Oncimmune
Oncimmune has developed a powerful new approach to the early diagnosis of primary cancer, cancer recurrence and the clinical management of cancer.
Healthcare: Diagnostics – cancer
School of Medicine
Profile
Oncimmune has developed a powerful new approach to the early diagnosis of primary cancer, cancer recurrence and the clinical management of cancer.
The technology is based on serum assays that detect auto-antibody formation to known cancer antigens with the clinical utility of early diagnosis of cancer.
This breakthrough is currently applied to lung cancer through the development of a blood test EarlyCDT®, but will be extended to the detection of other common cancers such as breast, colorectal, ovarian and prostate.
The company is based in customised laboratory and office space at Nottingham City Hospital, and began trading on AIM in May 2016.
News and press releases
Our sale of shares represents a significant return on our original investment in Oncimmune and the company is an exemplar of what can be done when a technology is successfully spun out from the University of Nottingham. It has been a pleasure to see Oncimmune grow into a leading early cancer detection company that is already saving lives and is on track to save many more. We look to the future with confidence as the company has the management and strategy in place to deliver value and we are delighted to retain a significant shareholding
Dr Andrew Naylor
Chief executive – Nottingham Technology Ventures
@OncimmuneECDT on Twitter
Thank you to @7NewsMelbourne for helping us raise awareness in Australia of the EarlyCDT lung blood test and its potential to save so many lives through the early detection of #lungcancer
https://bit.ly/30GGn6T
#detectcancerearly #extratime
Thank you for your support @SheronBoyle1. Last week our landmark ECLS trial was published in the European Respiratory Journal @EuroRespSoc. A peer reviewed publication will help to drive our campaign for adoption of EarlyCDT Lung by the @NHSuk @NHSScotland
#lungcancer #ExtraTime
Thank you to @itvnews for this important piece to help raise awareness of the EarlyCDT Lung blood test.
#lungcancer #DetectCancerEarly #ExtraTime
"This breakthrough could lead to early intervention, making surgery an option, ultimately prolonging or saving lives and reducing the burden on the NHS"
The EarlyCDT Lung blood test featured @itvnews today
#lungcancer #lungcancerscreening #extratime
New blood test provides breakthrough in lung cancer detection rates | ITV News
Taking the EarlyCDT-Lung blood test resulted in a 36% reduction in late stage lung cancer diagnosis compared to standard clinical practice.
bit.ly
@ZaksTradersCafe speaks with Adam Hill @Tech_Trender
about the latest evidence that supports the use of the EarlyCDT Lung blood test for the early detection of #lungcancer
#lungcancerscreening #extratime
Dr Adam M Hill @Tech_Trender talks with Dr @IanWCampbell, Executive Chair at @innovateuk, about how the #COVID19 pandemic has impacted innovation in the UK plus the challenges and opportunities for #diagnostics coming out of the pandemic #extratime
https://open.spotify.com/show/29sqARNJvje6bzhkMTn2B1
@OncimmuneECDT Listen to Oncimmune's Extra Time podcasts https://biopartner.co.uk/oncimmune.php via @BioPartner
Drs. Skibo and Bhadra are discussing management of incidental lung nodules in this @GO2Foundation hosted webinar TODAY. #LungCancer https://twitter.com/BiodesixInc/status/1288946184283815936
Gallery
